Medpace Holdings' Resilience Amid Biopharma Funding Concerns Catches Giverny Capital's Attention

Giverny Capital has highlighted Medpace Holdings (NasdaqGS:MEDP) for its resilience during market uncertainty, citing a substantial share repurchase earlier in the year as a sign of management confidence. The asset manager points to Medpace's response to concerns around biopharmaceutical funding and investor sentiment. The stock has seen a 71.3% return over the past year and a 153.9% return over three years.